Medpage Today on MSN2d
First Drug OK'd for Chronic Rhinosinusitis With Nasal Polyps in Adolescents
The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
Yahoo Finance6d
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
In the SINUS-24 and SINUS-52 trials, Dupixent significantly improved nasal congestion/obstruction severity, nasal polyp size and sense ... with moderate-to-severe asthma and adult patients with ...
Zacks.com on MSN3d
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Hosted on MSN12d
What Are Nasal Polyps?
Nasal polyps are benign (non-cancerous) growths that develop inside the nose or sinuses. Common causes of nasal polyps include asthma, allergies, and chronic sinus infections. Nasal polyps are ...
GlobalData on MSN3d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.
pharmaphorum1d
Respiratory biotech Upstream joins Nasdaq IPO surge
The Waltham, Massachusetts-based company has advanced its TSLP inhibitor verekitug into a pair of phase 2 trials in severe ...